| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 123 | 2026 | 410 | 23.970 |
Why?
|
| Hypertension, Pulmonary | 161 | 2025 | 1948 | 17.160 |
Why?
|
| Nitric Oxide | 116 | 2023 | 894 | 11.400 |
Why?
|
| Lung | 139 | 2026 | 4089 | 10.580 |
Why?
|
| Persistent Fetal Circulation Syndrome | 49 | 2023 | 137 | 9.530 |
Why?
|
| Infant, Premature | 79 | 2026 | 614 | 9.050 |
Why?
|
| Pulmonary Circulation | 78 | 2022 | 429 | 7.210 |
Why?
|
| Infant, Newborn | 215 | 2026 | 6399 | 5.820 |
Why?
|
| Pulmonary Artery | 75 | 2025 | 1124 | 5.660 |
Why?
|
| Pulmonary Alveoli | 31 | 2023 | 383 | 5.400 |
Why?
|
| Animals, Newborn | 59 | 2025 | 890 | 4.540 |
Why?
|
| Fetus | 58 | 2019 | 800 | 3.970 |
Why?
|
| Sheep | 94 | 2018 | 880 | 3.730 |
Why?
|
| Vascular Resistance | 51 | 2024 | 368 | 3.570 |
Why?
|
| Vascular Endothelial Growth Factor A | 26 | 2025 | 550 | 3.260 |
Why?
|
| Respiratory Insufficiency | 21 | 2023 | 324 | 3.260 |
Why?
|
| Vasodilator Agents | 22 | 2023 | 329 | 3.120 |
Why?
|
| Pediatrics | 20 | 2024 | 1121 | 3.100 |
Why?
|
| Hyperoxia | 11 | 2024 | 96 | 3.100 |
Why?
|
| Administration, Inhalation | 77 | 2023 | 570 | 2.930 |
Why?
|
| Respiration, Artificial | 37 | 2025 | 710 | 2.880 |
Why?
|
| Neonatology | 4 | 2026 | 32 | 2.860 |
Why?
|
| Nitric Oxide Synthase | 34 | 2007 | 234 | 2.820 |
Why?
|
| Lung Diseases | 20 | 2024 | 781 | 2.660 |
Why?
|
| Vasodilation | 36 | 2011 | 520 | 2.620 |
Why?
|
| Infant, Premature, Diseases | 11 | 2023 | 112 | 2.490 |
Why?
|
| Neovascularization, Physiologic | 15 | 2015 | 191 | 2.400 |
Why?
|
| Hemodynamics | 54 | 2025 | 1113 | 2.300 |
Why?
|
| Racism | 5 | 2022 | 155 | 2.300 |
Why?
|
| Premature Birth | 11 | 2024 | 376 | 2.300 |
Why?
|
| Infant | 100 | 2026 | 10023 | 2.170 |
Why?
|
| Hypoxia | 35 | 2023 | 1193 | 2.160 |
Why?
|
| Chorioamnionitis | 7 | 2026 | 49 | 2.150 |
Why?
|
| Humans | 335 | 2026 | 144667 | 2.140 |
Why?
|
| Gestational Age | 43 | 2026 | 980 | 2.110 |
Why?
|
| Pregnancy | 86 | 2026 | 7122 | 2.080 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 15 | 2021 | 106 | 2.070 |
Why?
|
| Endothelial Cells | 20 | 2024 | 864 | 2.050 |
Why?
|
| Endothelium, Vascular | 22 | 2024 | 949 | 1.970 |
Why?
|
| Infant, Extremely Premature | 9 | 2025 | 68 | 1.910 |
Why?
|
| rho-Associated Kinases | 7 | 2016 | 82 | 1.890 |
Why?
|
| Vascular Diseases | 8 | 2023 | 252 | 1.840 |
Why?
|
| Social Justice | 3 | 2020 | 82 | 1.830 |
Why?
|
| Rats | 44 | 2026 | 5570 | 1.780 |
Why?
|
| Animals | 163 | 2026 | 37948 | 1.760 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 16 | 2024 | 221 | 1.750 |
Why?
|
| Endothelin-1 | 17 | 2016 | 181 | 1.740 |
Why?
|
| Lung Injury | 5 | 2024 | 236 | 1.720 |
Why?
|
| Endotoxins | 10 | 2026 | 218 | 1.710 |
Why?
|
| Oxygen | 31 | 2023 | 984 | 1.700 |
Why?
|
| Rats, Sprague-Dawley | 33 | 2026 | 2521 | 1.690 |
Why?
|
| Female | 197 | 2026 | 78304 | 1.520 |
Why?
|
| Oxygen Inhalation Therapy | 15 | 2019 | 181 | 1.510 |
Why?
|
| Nitric Oxide Synthase Type III | 26 | 2016 | 203 | 1.410 |
Why?
|
| Ductus Arteriosus | 19 | 2012 | 72 | 1.370 |
Why?
|
| Sulfones | 7 | 2013 | 127 | 1.360 |
Why?
|
| Phosphodiesterase Inhibitors | 9 | 2019 | 72 | 1.340 |
Why?
|
| Cardiac Catheterization | 19 | 2025 | 557 | 1.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 9 | 2020 | 108 | 1.250 |
Why?
|
| Disease Models, Animal | 30 | 2026 | 4539 | 1.240 |
Why?
|
| High-Frequency Ventilation | 14 | 2002 | 45 | 1.240 |
Why?
|
| T-Box Domain Proteins | 4 | 2025 | 106 | 1.230 |
Why?
|
| Societies, Medical | 6 | 2024 | 890 | 1.220 |
Why?
|
| Cyclic GMP | 11 | 2011 | 90 | 1.220 |
Why?
|
| Piperazines | 7 | 2013 | 378 | 1.210 |
Why?
|
| Guanylate Cyclase | 6 | 2022 | 38 | 1.200 |
Why?
|
| Bronchodilator Agents | 12 | 2019 | 184 | 1.190 |
Why?
|
| Indoles | 10 | 2024 | 504 | 1.190 |
Why?
|
| Fetal Blood | 6 | 2017 | 325 | 1.190 |
Why?
|
| Endothelins | 13 | 2009 | 61 | 1.190 |
Why?
|
| Child | 74 | 2025 | 22600 | 1.160 |
Why?
|
| Biomedical Research | 6 | 2026 | 712 | 1.150 |
Why?
|
| Child Health | 2 | 2020 | 153 | 1.140 |
Why?
|
| Vitamin D | 5 | 2020 | 400 | 1.130 |
Why?
|
| Mentors | 3 | 2021 | 214 | 1.120 |
Why?
|
| Hypertrophy, Right Ventricular | 16 | 2025 | 149 | 1.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2017 | 103 | 1.030 |
Why?
|
| Health Status Disparities | 2 | 2020 | 318 | 1.010 |
Why?
|
| Receptors, Endothelin | 9 | 2016 | 48 | 1.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 5 | 2022 | 74 | 0.990 |
Why?
|
| Pulmonary Medicine | 5 | 2021 | 78 | 0.990 |
Why?
|
| Fetal Diseases | 10 | 2007 | 193 | 0.990 |
Why?
|
| Male | 123 | 2026 | 72431 | 0.950 |
Why?
|
| Social Determinants of Health | 2 | 2020 | 305 | 0.950 |
Why?
|
| Infant Health | 1 | 2026 | 25 | 0.940 |
Why?
|
| Pulmonary Veins | 6 | 2014 | 104 | 0.930 |
Why?
|
| Echocardiography, Doppler | 4 | 2018 | 114 | 0.930 |
Why?
|
| Infant, Very Low Birth Weight | 7 | 2019 | 74 | 0.920 |
Why?
|
| Hernia, Diaphragmatic | 10 | 2014 | 67 | 0.900 |
Why?
|
| Vasoconstriction | 9 | 2008 | 216 | 0.890 |
Why?
|
| Endothelin Receptor Antagonists | 7 | 2013 | 61 | 0.880 |
Why?
|
| SOXF Transcription Factors | 1 | 2024 | 16 | 0.870 |
Why?
|
| Signal Transduction | 23 | 2025 | 5185 | 0.860 |
Why?
|
| Down Syndrome | 5 | 2022 | 522 | 0.840 |
Why?
|
| Echocardiography | 15 | 2025 | 644 | 0.840 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2026 | 641 | 0.840 |
Why?
|
| Immunohistochemistry | 16 | 2020 | 1705 | 0.830 |
Why?
|
| Precision Medicine | 3 | 2026 | 454 | 0.830 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2023 | 35 | 0.830 |
Why?
|
| Stem Cells | 5 | 2013 | 621 | 0.820 |
Why?
|
| Respiratory Tract Diseases | 3 | 2019 | 175 | 0.820 |
Why?
|
| Dipyridamole | 7 | 1998 | 28 | 0.820 |
Why?
|
| Phenotype | 15 | 2026 | 3147 | 0.820 |
Why?
|
| Child, Preschool | 50 | 2025 | 11790 | 0.810 |
Why?
|
| Surface Plasmon Resonance | 2 | 2021 | 88 | 0.810 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 736 | 0.790 |
Why?
|
| Infant, Low Birth Weight | 4 | 2020 | 154 | 0.780 |
Why?
|
| Sildenafil Citrate | 9 | 2021 | 60 | 0.780 |
Why?
|
| Respiratory Function Tests | 11 | 2026 | 541 | 0.770 |
Why?
|
| Muscle, Smooth, Vascular | 10 | 2009 | 441 | 0.760 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2023 | 317 | 0.760 |
Why?
|
| Interprofessional Relations | 1 | 2025 | 275 | 0.760 |
Why?
|
| Physicians | 3 | 2018 | 949 | 0.730 |
Why?
|
| Nitroarginine | 19 | 2007 | 57 | 0.730 |
Why?
|
| Heart Ventricles | 5 | 2021 | 751 | 0.720 |
Why?
|
| Pulmonary Surfactants | 6 | 2024 | 103 | 0.720 |
Why?
|
| Pulmonary Gas Exchange | 10 | 2022 | 116 | 0.710 |
Why?
|
| Career Choice | 3 | 2014 | 233 | 0.710 |
Why?
|
| Placenta | 7 | 2024 | 781 | 0.700 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2013 | 104 | 0.700 |
Why?
|
| Vitamin D Deficiency | 3 | 2020 | 187 | 0.700 |
Why?
|
| Lung Compliance | 2 | 2020 | 42 | 0.690 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2022 | 392 | 0.690 |
Why?
|
| Child Welfare | 2 | 2014 | 231 | 0.690 |
Why?
|
| Bronchial Arteries | 2 | 2018 | 12 | 0.690 |
Why?
|
| Cystic Fibrosis | 15 | 2021 | 1166 | 0.670 |
Why?
|
| Enzyme Activation | 5 | 2012 | 762 | 0.670 |
Why?
|
| Peptide PHI | 1 | 2020 | 2 | 0.660 |
Why?
|
| Disease Management | 4 | 2019 | 650 | 0.660 |
Why?
|
| Early Diagnosis | 3 | 2021 | 249 | 0.650 |
Why?
|
| Chronic Disease | 22 | 2019 | 1810 | 0.650 |
Why?
|
| Glycogen Storage Disease | 1 | 2020 | 19 | 0.640 |
Why?
|
| Neovascularization, Pathologic | 4 | 2015 | 284 | 0.640 |
Why?
|
| Hypertension | 5 | 2023 | 1262 | 0.640 |
Why?
|
| Pregnancy, Animal | 1 | 2020 | 51 | 0.640 |
Why?
|
| Benzoates | 2 | 2011 | 50 | 0.640 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2020 | 69 | 0.630 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 3 | 2021 | 17 | 0.630 |
Why?
|
| Blotting, Western | 13 | 2020 | 1161 | 0.630 |
Why?
|
| Bleomycin | 4 | 2016 | 253 | 0.620 |
Why?
|
| Angiogenic Proteins | 1 | 2020 | 15 | 0.620 |
Why?
|
| Serotonin | 2 | 2013 | 294 | 0.620 |
Why?
|
| Trachea | 5 | 2017 | 258 | 0.610 |
Why?
|
| Birth Weight | 5 | 2020 | 506 | 0.610 |
Why?
|
| Pyrroles | 9 | 2020 | 213 | 0.610 |
Why?
|
| Familial Primary Pulmonary Hypertension | 8 | 2023 | 196 | 0.610 |
Why?
|
| Cooperative Behavior | 3 | 2025 | 464 | 0.610 |
Why?
|
| Vascular Stiffness | 5 | 2019 | 485 | 0.600 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 20 | 0.600 |
Why?
|
| Tracheostomy | 7 | 2025 | 142 | 0.600 |
Why?
|
| Cells, Cultured | 17 | 2016 | 4110 | 0.600 |
Why?
|
| Postnatal Care | 1 | 2020 | 76 | 0.600 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 223 | 0.580 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2016 | 33 | 0.580 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 171 | 0.580 |
Why?
|
| Emphysema | 1 | 2020 | 100 | 0.580 |
Why?
|
| Enzyme Inhibitors | 16 | 2009 | 820 | 0.580 |
Why?
|
| Blood Pressure | 28 | 2019 | 1766 | 0.570 |
Why?
|
| Heart Defects, Congenital | 15 | 2024 | 905 | 0.570 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2011 | 204 | 0.570 |
Why?
|
| Arteriovenous Anastomosis | 3 | 2022 | 13 | 0.560 |
Why?
|
| Acetylcholine | 11 | 2009 | 208 | 0.560 |
Why?
|
| Smoking | 4 | 2026 | 1467 | 0.560 |
Why?
|
| Follow-Up Studies | 17 | 2026 | 5414 | 0.560 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 4 | 2016 | 28 | 0.550 |
Why?
|
| Protein Precursors | 6 | 2000 | 136 | 0.550 |
Why?
|
| Pyridines | 6 | 2012 | 603 | 0.550 |
Why?
|
| Vitamins | 6 | 2019 | 176 | 0.550 |
Why?
|
| Superoxide Dismutase | 5 | 2015 | 303 | 0.540 |
Why?
|
| Pulmonary Emphysema | 2 | 2020 | 275 | 0.540 |
Why?
|
| Antihypertensive Agents | 8 | 2019 | 512 | 0.540 |
Why?
|
| Prospective Studies | 19 | 2025 | 7994 | 0.540 |
Why?
|
| Science | 2 | 2016 | 56 | 0.540 |
Why?
|
| United States | 23 | 2024 | 16018 | 0.540 |
Why?
|
| Health Equity | 1 | 2020 | 132 | 0.530 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 669 | 0.530 |
Why?
|
| Bone Marrow Cells | 3 | 2009 | 321 | 0.520 |
Why?
|
| Inflammation | 4 | 2025 | 2870 | 0.510 |
Why?
|
| Epoprostenol | 5 | 2021 | 132 | 0.510 |
Why?
|
| Longevity | 1 | 2018 | 175 | 0.510 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 8 | 2015 | 86 | 0.510 |
Why?
|
| Fetal Growth Retardation | 6 | 2022 | 591 | 0.500 |
Why?
|
| Cardiology | 1 | 2020 | 359 | 0.500 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2016 | 906 | 0.490 |
Why?
|
| Collagen Type VIII | 1 | 2016 | 3 | 0.490 |
Why?
|
| Exosomes | 1 | 2018 | 104 | 0.490 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2016 | 9 | 0.490 |
Why?
|
| Respiration Disorders | 4 | 2019 | 78 | 0.490 |
Why?
|
| Infant Care | 1 | 2016 | 44 | 0.490 |
Why?
|
| Collagen Type IV | 1 | 2016 | 27 | 0.480 |
Why?
|
| Vascular Endothelial Growth Factors | 6 | 2022 | 78 | 0.480 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 172 | 0.480 |
Why?
|
| Pulmonary Wedge Pressure | 7 | 2022 | 66 | 0.480 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 267 | 0.480 |
Why?
|
| Ventilator Weaning | 5 | 2024 | 39 | 0.480 |
Why?
|
| Estradiol | 4 | 2001 | 507 | 0.480 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2016 | 64 | 0.480 |
Why?
|
| Academies and Institutes | 1 | 2016 | 58 | 0.470 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2017 | 581 | 0.470 |
Why?
|
| Pre-Eclampsia | 3 | 2022 | 203 | 0.470 |
Why?
|
| PPAR gamma | 2 | 2013 | 177 | 0.470 |
Why?
|
| Endothelial Growth Factors | 4 | 2003 | 62 | 0.470 |
Why?
|
| Organ Size | 10 | 2009 | 461 | 0.460 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 6 | 2006 | 17 | 0.460 |
Why?
|
| Congresses as Topic | 2 | 2014 | 221 | 0.460 |
Why?
|
| Lymphokines | 4 | 2003 | 128 | 0.460 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2015 | 18 | 0.460 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 448 | 0.460 |
Why?
|
| Bronchi | 5 | 2021 | 263 | 0.460 |
Why?
|
| Altitude | 3 | 2022 | 473 | 0.460 |
Why?
|
| Pulmonary Edema | 4 | 2008 | 105 | 0.450 |
Why?
|
| Risk | 8 | 2021 | 911 | 0.450 |
Why?
|
| Retrospective Studies | 37 | 2025 | 17149 | 0.450 |
Why?
|
| Primary Prevention | 2 | 2014 | 217 | 0.450 |
Why?
|
| Receptors, Calcitriol | 1 | 2015 | 55 | 0.450 |
Why?
|
| Hospitalization | 4 | 2015 | 2446 | 0.450 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 545 | 0.440 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 2922 | 0.440 |
Why?
|
| Endpoint Determination | 1 | 2015 | 84 | 0.440 |
Why?
|
| Faculty, Medical | 1 | 2018 | 301 | 0.440 |
Why?
|
| Registries | 6 | 2025 | 2392 | 0.440 |
Why?
|
| Early Medical Intervention | 2 | 2014 | 61 | 0.430 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 165 | 0.430 |
Why?
|
| Intensive Care Units, Neonatal | 6 | 2025 | 287 | 0.430 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 300 | 0.420 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2021 | 213 | 0.420 |
Why?
|
| Capillaries | 2 | 2015 | 118 | 0.420 |
Why?
|
| Radiology | 1 | 2017 | 174 | 0.420 |
Why?
|
| Adventitia | 1 | 2014 | 42 | 0.420 |
Why?
|
| Pyrazoles | 4 | 2022 | 512 | 0.420 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2017 | 113 | 0.420 |
Why?
|
| Risk Factors | 20 | 2025 | 10796 | 0.410 |
Why?
|
| Time Factors | 22 | 2024 | 7140 | 0.410 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 660 | 0.410 |
Why?
|
| Body Weight | 12 | 2009 | 968 | 0.400 |
Why?
|
| Hyaline Membrane Disease | 4 | 1998 | 20 | 0.400 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 57 | 0.400 |
Why?
|
| Isoenzymes | 3 | 2011 | 297 | 0.400 |
Why?
|
| Patient Care Team | 5 | 2024 | 690 | 0.400 |
Why?
|
| Purines | 6 | 2013 | 187 | 0.390 |
Why?
|
| Gene Expression | 5 | 2023 | 1476 | 0.390 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 264 | 0.390 |
Why?
|
| Ventricular Dysfunction, Right | 5 | 2019 | 248 | 0.390 |
Why?
|
| Autoantigens | 1 | 2016 | 425 | 0.390 |
Why?
|
| Mentoring | 1 | 2016 | 164 | 0.390 |
Why?
|
| Treatment Outcome | 26 | 2024 | 11735 | 0.390 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2013 | 18 | 0.390 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2006 | 161 | 0.380 |
Why?
|
| Arterial Pressure | 3 | 2019 | 133 | 0.380 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 111 | 0.380 |
Why?
|
| Internship and Residency | 2 | 2014 | 1262 | 0.380 |
Why?
|
| Betamethasone | 2 | 2024 | 21 | 0.380 |
Why?
|
| Blood Vessels | 4 | 2016 | 167 | 0.380 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2003 | 376 | 0.370 |
Why?
|
| Extracorporeal Membrane Oxygenation | 13 | 2015 | 387 | 0.370 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 106 | 0.370 |
Why?
|
| Reference Values | 9 | 2020 | 794 | 0.370 |
Why?
|
| Ventricular Function, Right | 6 | 2021 | 296 | 0.370 |
Why?
|
| Umbilical Cord | 1 | 2013 | 92 | 0.370 |
Why?
|
| Adolescent | 28 | 2025 | 22409 | 0.370 |
Why?
|
| Forkhead Transcription Factors | 3 | 2023 | 203 | 0.370 |
Why?
|
| Amides | 3 | 2012 | 99 | 0.360 |
Why?
|
| Potassium Channels | 3 | 2000 | 145 | 0.360 |
Why?
|
| Vasomotor System | 6 | 2002 | 46 | 0.350 |
Why?
|
| MicroRNAs | 1 | 2018 | 689 | 0.350 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 2172 | 0.350 |
Why?
|
| Age Factors | 11 | 2019 | 3329 | 0.350 |
Why?
|
| Home Care Services | 4 | 2024 | 280 | 0.340 |
Why?
|
| In Vitro Techniques | 6 | 2020 | 1046 | 0.340 |
Why?
|
| Embryonic and Fetal Development | 7 | 2002 | 93 | 0.340 |
Why?
|
| Organogenesis | 1 | 2011 | 63 | 0.330 |
Why?
|
| Mothers | 1 | 2017 | 765 | 0.330 |
Why?
|
| History, 20th Century | 3 | 2017 | 327 | 0.330 |
Why?
|
| Cell Proliferation | 8 | 2015 | 2489 | 0.320 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2018 | 120 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 2019 | 0.310 |
Why?
|
| Prostaglandins | 4 | 2007 | 94 | 0.310 |
Why?
|
| Atrial Natriuretic Factor | 3 | 1996 | 55 | 0.310 |
Why?
|
| Risk Assessment | 9 | 2024 | 3729 | 0.300 |
Why?
|
| Health Status Indicators | 2 | 2020 | 167 | 0.300 |
Why?
|
| Culturally Competent Care | 2 | 2020 | 73 | 0.300 |
Why?
|
| Piperidines | 3 | 2016 | 219 | 0.300 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 301 | 0.300 |
Why?
|
| Cultural Diversity | 2 | 2020 | 85 | 0.300 |
Why?
|
| Oligopeptides | 3 | 2016 | 266 | 0.300 |
Why?
|
| Vascular Remodeling | 2 | 2025 | 203 | 0.290 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 454 | 0.290 |
Why?
|
| Survival Rate | 11 | 2017 | 2089 | 0.290 |
Why?
|
| Regional Blood Flow | 6 | 2021 | 513 | 0.290 |
Why?
|
| Adult | 25 | 2026 | 40489 | 0.280 |
Why?
|
| Calcium Channel Blockers | 3 | 2007 | 165 | 0.280 |
Why?
|
| Mice, Knockout | 6 | 2025 | 3109 | 0.280 |
Why?
|
| Arginine | 7 | 1994 | 238 | 0.280 |
Why?
|
| Endothelium | 3 | 2015 | 119 | 0.280 |
Why?
|
| Biomarkers | 7 | 2026 | 4261 | 0.270 |
Why?
|
| Endothelin B Receptor Antagonists | 2 | 2005 | 12 | 0.270 |
Why?
|
| Patient Discharge | 4 | 2025 | 985 | 0.270 |
Why?
|
| Phenyl Ethers | 1 | 2007 | 5 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2002 | 230 | 0.270 |
Why?
|
| Receptors, Growth Factor | 3 | 2002 | 53 | 0.270 |
Why?
|
| Aorta | 7 | 2017 | 427 | 0.270 |
Why?
|
| Asthma | 2 | 2021 | 1774 | 0.270 |
Why?
|
| Iloprost | 1 | 2008 | 45 | 0.270 |
Why?
|
| Fluorocarbons | 2 | 1999 | 119 | 0.260 |
Why?
|
| Recombinant Proteins | 6 | 2006 | 1363 | 0.260 |
Why?
|
| RNA, Messenger | 12 | 2014 | 2815 | 0.260 |
Why?
|
| Home Nursing | 3 | 2003 | 23 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2008 | 971 | 0.260 |
Why?
|
| Steroids | 3 | 2024 | 159 | 0.260 |
Why?
|
| Labor, Obstetric | 2 | 2001 | 67 | 0.250 |
Why?
|
| Cohort Studies | 10 | 2024 | 5957 | 0.250 |
Why?
|
| Oxadiazoles | 3 | 2011 | 37 | 0.250 |
Why?
|
| Ductus Arteriosus, Patent | 3 | 2023 | 50 | 0.250 |
Why?
|
| Respiratory Sounds | 2 | 2025 | 103 | 0.240 |
Why?
|
| Neonatal Screening | 7 | 1993 | 179 | 0.240 |
Why?
|
| Ligation | 5 | 2012 | 91 | 0.240 |
Why?
|
| Mice | 11 | 2026 | 18261 | 0.240 |
Why?
|
| Uteroglobin | 1 | 2026 | 30 | 0.240 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 370 | 0.240 |
Why?
|
| Positive-Pressure Respiration | 4 | 2023 | 112 | 0.240 |
Why?
|
| Receptor, Endothelin B | 6 | 2004 | 43 | 0.240 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 779 | 0.230 |
Why?
|
| Disease Progression | 5 | 2018 | 2847 | 0.230 |
Why?
|
| Glucocorticoids | 2 | 2000 | 528 | 0.230 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2026 | 919 | 0.230 |
Why?
|
| Apoptosis | 4 | 2013 | 2397 | 0.230 |
Why?
|
| Logistic Models | 4 | 2020 | 2114 | 0.230 |
Why?
|
| Prognosis | 10 | 2019 | 4312 | 0.230 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.220 |
Why?
|
| Tracheobronchomalacia | 1 | 2025 | 15 | 0.220 |
Why?
|
| Antigens, CD | 1 | 2008 | 552 | 0.220 |
Why?
|
| Monitoring, Physiologic | 4 | 2019 | 288 | 0.220 |
Why?
|
| Research Personnel | 3 | 2020 | 185 | 0.220 |
Why?
|
| Blotting, Northern | 6 | 2002 | 203 | 0.220 |
Why?
|
| Sulfonamides | 5 | 2016 | 579 | 0.220 |
Why?
|
| Vital Capacity | 1 | 2026 | 290 | 0.220 |
Why?
|
| Ventricular Function, Left | 4 | 2017 | 536 | 0.220 |
Why?
|
| Morbidity | 2 | 2023 | 322 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 779 | 0.220 |
Why?
|
| Analysis of Variance | 7 | 2012 | 1301 | 0.220 |
Why?
|
| Peptides, Cyclic | 5 | 2016 | 275 | 0.220 |
Why?
|
| Antioxidants | 3 | 2013 | 546 | 0.220 |
Why?
|
| Amniotic Fluid | 3 | 2018 | 79 | 0.210 |
Why?
|
| Bacteria | 1 | 2011 | 894 | 0.210 |
Why?
|
| History, 21st Century | 2 | 2017 | 220 | 0.210 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1268 | 0.210 |
Why?
|
| Infant Mortality | 1 | 2025 | 126 | 0.210 |
Why?
|
| Respiratory Therapy | 2 | 1994 | 25 | 0.210 |
Why?
|
| Gastroesophageal Reflux | 3 | 2024 | 236 | 0.200 |
Why?
|
| Asperger Syndrome | 1 | 2023 | 8 | 0.200 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 282 | 0.200 |
Why?
|
| Syndrome | 1 | 2024 | 379 | 0.200 |
Why?
|
| Fetal Development | 3 | 2022 | 295 | 0.200 |
Why?
|
| Prenatal Care | 3 | 2020 | 306 | 0.200 |
Why?
|
| Models, Animal | 2 | 2020 | 393 | 0.200 |
Why?
|
| Prevalence | 5 | 2025 | 2839 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1569 | 0.190 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 131 | 0.190 |
Why?
|
| Periodicals as Topic | 2 | 2017 | 206 | 0.190 |
Why?
|
| Respiratory System Agents | 1 | 2023 | 22 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3888 | 0.190 |
Why?
|
| Placenta Growth Factor | 2 | 2022 | 26 | 0.190 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 85 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 364 | 0.190 |
Why?
|
| Fatal Outcome | 4 | 2018 | 305 | 0.190 |
Why?
|
| Ketanserin | 2 | 2013 | 12 | 0.190 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2013 | 10 | 0.190 |
Why?
|
| Nitrites | 1 | 2002 | 89 | 0.190 |
Why?
|
| Physicians, Women | 2 | 2014 | 88 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 176 | 0.180 |
Why?
|
| Lung Transplantation | 4 | 2024 | 329 | 0.180 |
Why?
|
| Sertraline | 2 | 2013 | 27 | 0.180 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2022 | 15 | 0.180 |
Why?
|
| Interdisciplinary Research | 1 | 2022 | 26 | 0.180 |
Why?
|
| Meconium Aspiration Syndrome | 3 | 2015 | 11 | 0.180 |
Why?
|
| Oxidative Stress | 3 | 2018 | 1338 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2025 | 253 | 0.180 |
Why?
|
| Air Pollution, Indoor | 1 | 2024 | 182 | 0.180 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 4 | 2006 | 23 | 0.180 |
Why?
|
| Achievement | 1 | 2022 | 58 | 0.180 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 717 | 0.180 |
Why?
|
| Sudden Infant Death | 1 | 2022 | 39 | 0.180 |
Why?
|
| Angiography | 7 | 2002 | 208 | 0.180 |
Why?
|
| Longitudinal Studies | 6 | 2025 | 2942 | 0.180 |
Why?
|
| Proteomics | 2 | 2020 | 1183 | 0.180 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 63 | 0.180 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 37 | 0.170 |
Why?
|
| Receptor, Endothelin A | 5 | 2000 | 60 | 0.170 |
Why?
|
| Uterus | 1 | 2002 | 224 | 0.170 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 18 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 2350 | 0.170 |
Why?
|
| Young Adult | 10 | 2023 | 14122 | 0.170 |
Why?
|
| Transcription Factors | 3 | 2023 | 1726 | 0.170 |
Why?
|
| Amino Acids, Dicarboxylic | 1 | 2020 | 9 | 0.160 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 49 | 0.160 |
Why?
|
| Pleural Effusion | 1 | 2021 | 59 | 0.160 |
Why?
|
| Milrinone | 1 | 2021 | 26 | 0.160 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 35 | 0.160 |
Why?
|
| Soluble Guanylyl Cyclase | 2 | 2011 | 15 | 0.160 |
Why?
|
| Emergency Treatment | 1 | 2002 | 124 | 0.160 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 82 | 0.160 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2000 | 55 | 0.160 |
Why?
|
| Pneumonia | 2 | 2022 | 629 | 0.160 |
Why?
|
| Interactive Ventilatory Support | 1 | 2020 | 2 | 0.160 |
Why?
|
| Causality | 2 | 2018 | 126 | 0.160 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 266 | 0.160 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 296 | 0.160 |
Why?
|
| Stress, Mechanical | 5 | 2019 | 494 | 0.160 |
Why?
|
| Microbiota | 2 | 2018 | 782 | 0.160 |
Why?
|
| Current Procedural Terminology | 1 | 2020 | 19 | 0.160 |
Why?
|
| Quinoxalines | 2 | 2011 | 64 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 572 | 0.150 |
Why?
|
| Trust | 1 | 2021 | 155 | 0.150 |
Why?
|
| Colony-Forming Units Assay | 2 | 2009 | 95 | 0.150 |
Why?
|
| Heart Function Tests | 1 | 2019 | 59 | 0.150 |
Why?
|
| Random Allocation | 1 | 2020 | 366 | 0.150 |
Why?
|
| Blood Flow Velocity | 4 | 2019 | 419 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 172 | 0.150 |
Why?
|
| Morphogenesis | 2 | 2013 | 172 | 0.150 |
Why?
|
| Transportation of Patients | 2 | 2002 | 67 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1742 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 1056 | 0.140 |
Why?
|
| Scurvy | 1 | 2019 | 17 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 339 | 0.140 |
Why?
|
| Potassium Channel Blockers | 1 | 1999 | 47 | 0.140 |
Why?
|
| Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.140 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 65 | 0.140 |
Why?
|
| Colorado | 5 | 2017 | 4558 | 0.140 |
Why?
|
| Respiratory Tract Infections | 3 | 2021 | 395 | 0.140 |
Why?
|
| Vitamin A | 3 | 2019 | 59 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 1537 | 0.140 |
Why?
|
| Receptors, Estrogen | 1 | 2001 | 400 | 0.140 |
Why?
|
| Maternal Exposure | 2 | 2012 | 185 | 0.140 |
Why?
|
| Natural Language Processing | 1 | 2020 | 103 | 0.140 |
Why?
|
| Constriction | 3 | 2008 | 46 | 0.140 |
Why?
|
| Coculture Techniques | 2 | 2016 | 245 | 0.140 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 22 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 25 | 0.140 |
Why?
|
| Myocardial Contraction | 2 | 2019 | 288 | 0.140 |
Why?
|
| Intubation, Intratracheal | 3 | 2017 | 323 | 0.130 |
Why?
|
| Serum Albumin | 3 | 1992 | 144 | 0.130 |
Why?
|
| Phosphorylation | 3 | 2015 | 1704 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 16 | 0.130 |
Why?
|
| Placental Insufficiency | 2 | 2014 | 126 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2019 | 392 | 0.130 |
Why?
|
| Incidence | 6 | 2015 | 2892 | 0.130 |
Why?
|
| Air | 2 | 2009 | 45 | 0.130 |
Why?
|
| Elastin | 2 | 2015 | 78 | 0.130 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 85 | 0.130 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 3414 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2017 | 564 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2000 | 366 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2019 | 1370 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2007 | 238 | 0.130 |
Why?
|
| Refractometry | 1 | 2017 | 29 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 259 | 0.130 |
Why?
|
| Respiratory System | 1 | 2018 | 151 | 0.130 |
Why?
|
| Stroke Volume | 2 | 2018 | 650 | 0.130 |
Why?
|
| Ventilators, Mechanical | 3 | 2021 | 71 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2017 | 61 | 0.130 |
Why?
|
| Education, Medical | 1 | 2020 | 273 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2012 | 1154 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2018 | 98 | 0.130 |
Why?
|
| Dysbiosis | 1 | 2018 | 187 | 0.120 |
Why?
|
| Methemoglobin | 2 | 1993 | 24 | 0.120 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 293 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 250 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1159 | 0.120 |
Why?
|
| Collagen Type XVIII | 1 | 2016 | 5 | 0.120 |
Why?
|
| Retinal Vessels | 1 | 2017 | 69 | 0.120 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 115 | 0.120 |
Why?
|
| Leukocyte Count | 2 | 2013 | 315 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2021 | 941 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 1997 | 132 | 0.120 |
Why?
|
| Altitude Sickness | 1 | 2018 | 141 | 0.120 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2019 | 35 | 0.120 |
Why?
|
| Dietary Supplements | 3 | 2019 | 575 | 0.120 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.120 |
Why?
|
| Scimitar Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 342 | 0.120 |
Why?
|
| Social Class | 1 | 2018 | 265 | 0.120 |
Why?
|
| Neutrophils | 3 | 2004 | 1118 | 0.120 |
Why?
|
| Hemoptysis | 1 | 2016 | 35 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 407 | 0.120 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cell Adhesion | 2 | 2016 | 452 | 0.110 |
Why?
|
| Veins | 1 | 2016 | 69 | 0.110 |
Why?
|
| Family | 1 | 2020 | 685 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 187 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 677 | 0.110 |
Why?
|
| Calcifediol | 1 | 2015 | 31 | 0.110 |
Why?
|
| Interleukin-1 | 1 | 1999 | 961 | 0.110 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.110 |
Why?
|
| Survivors | 1 | 2019 | 519 | 0.110 |
Why?
|
| Probability | 2 | 2008 | 309 | 0.110 |
Why?
|
| Respiration | 5 | 2018 | 206 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 1999 | 770 | 0.110 |
Why?
|
| Genetic Counseling | 1 | 2015 | 81 | 0.110 |
Why?
|
| Treatment Failure | 4 | 2007 | 365 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 869 | 0.110 |
Why?
|
| Cell Division | 2 | 2007 | 753 | 0.110 |
Why?
|
| Indiana | 1 | 2015 | 37 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3603 | 0.110 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 19 | 0.110 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 609 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 197 | 0.110 |
Why?
|
| Microvessels | 1 | 2016 | 98 | 0.110 |
Why?
|
| Nitroprusside | 2 | 2011 | 71 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2016 | 240 | 0.110 |
Why?
|
| Aging | 4 | 2007 | 1938 | 0.110 |
Why?
|
| Retina | 1 | 2017 | 319 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2019 | 480 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 1207 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 973 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 97 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 188 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 751 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 2014 | 38 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2950 | 0.100 |
Why?
|
| Taurine | 1 | 2014 | 41 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 6041 | 0.100 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2014 | 65 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 5967 | 0.100 |
Why?
|
| Vasopressins | 1 | 2014 | 60 | 0.100 |
Why?
|
| Embryo, Mammalian | 1 | 2014 | 232 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 492 | 0.100 |
Why?
|
| Developmental Disabilities | 2 | 2014 | 279 | 0.100 |
Why?
|
| Glycopeptides | 1 | 1994 | 44 | 0.100 |
Why?
|
| Sulfur | 1 | 2014 | 64 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 74 | 0.100 |
Why?
|
| Immunologic Techniques | 3 | 1999 | 38 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1928 | 0.100 |
Why?
|
| Cardiac Output | 3 | 2017 | 179 | 0.100 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 560 | 0.100 |
Why?
|
| Homocystinuria | 1 | 2014 | 62 | 0.100 |
Why?
|
| Schools, Medical | 1 | 2015 | 158 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 1 | 2014 | 144 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1322 | 0.100 |
Why?
|
| Collagen | 2 | 2014 | 450 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2016 | 848 | 0.100 |
Why?
|
| Sheep, Domestic | 1 | 2013 | 34 | 0.100 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2004 | 83 | 0.100 |
Why?
|
| Pain | 1 | 2019 | 785 | 0.100 |
Why?
|
| Transcriptome | 1 | 2020 | 1036 | 0.100 |
Why?
|
| Hypotension | 1 | 2014 | 126 | 0.100 |
Why?
|
| Acute Disease | 5 | 2005 | 1029 | 0.090 |
Why?
|
| Cysteine | 1 | 2014 | 207 | 0.090 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2013 | 54 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 197 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 51 | 0.090 |
Why?
|
| Pandemics | 1 | 2021 | 1700 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2013 | 79 | 0.090 |
Why?
|
| Molecular Biology | 1 | 2013 | 57 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 341 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2018 | 2037 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 74 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 1995 | 289 | 0.090 |
Why?
|
| Staining and Labeling | 4 | 1997 | 153 | 0.090 |
Why?
|
| Diastole | 2 | 2015 | 142 | 0.090 |
Why?
|
| Career Mobility | 1 | 2013 | 70 | 0.090 |
Why?
|
| Cadaver | 1 | 2013 | 305 | 0.090 |
Why?
|
| Airway Obstruction | 2 | 1984 | 153 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 73 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2025 | 426 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 139 | 0.090 |
Why?
|
| Decision Making | 1 | 2019 | 973 | 0.090 |
Why?
|
| Streptococcus agalactiae | 1 | 1993 | 109 | 0.090 |
Why?
|
| Pancreas | 1 | 2014 | 341 | 0.090 |
Why?
|
| Hysterotomy | 1 | 2011 | 9 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 205 | 0.090 |
Why?
|
| Cell Aggregation | 1 | 2011 | 19 | 0.090 |
Why?
|
| Carbon Dioxide | 3 | 2000 | 239 | 0.090 |
Why?
|
| DNA Primers | 1 | 2012 | 507 | 0.090 |
Why?
|
| Eicosanoids | 1 | 1992 | 58 | 0.090 |
Why?
|
| Receptors, Serotonin | 1 | 2011 | 34 | 0.090 |
Why?
|
| Suction | 1 | 2011 | 32 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 75 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2020 | 1176 | 0.090 |
Why?
|
| Bacterial Load | 1 | 2011 | 67 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2017 | 1287 | 0.090 |
Why?
|
| Guanidines | 3 | 2001 | 36 | 0.090 |
Why?
|
| Global Health | 2 | 2019 | 401 | 0.090 |
Why?
|
| Receptor, Insulin | 1 | 2011 | 93 | 0.080 |
Why?
|
| Hydrogels | 1 | 2018 | 703 | 0.080 |
Why?
|
| Antibodies | 1 | 1993 | 396 | 0.080 |
Why?
|
| Fluoxetine | 1 | 2011 | 54 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 170 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 341 | 0.080 |
Why?
|
| Primary Cell Culture | 1 | 2011 | 172 | 0.080 |
Why?
|
| RNA, Ribosomal | 1 | 2011 | 169 | 0.080 |
Why?
|
| RNA Interference | 1 | 2012 | 473 | 0.080 |
Why?
|
| Length of Stay | 2 | 2016 | 1339 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 776 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1484 | 0.080 |
Why?
|
| Metagenome | 1 | 2011 | 149 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 835 | 0.080 |
Why?
|
| RNA, Bacterial | 1 | 2011 | 193 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 248 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1501 | 0.080 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2001 | 65 | 0.080 |
Why?
|
| Rats, Inbred Strains | 2 | 2001 | 320 | 0.080 |
Why?
|
| Protein Binding | 1 | 2016 | 2243 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 427 | 0.080 |
Why?
|
| Forecasting | 1 | 2012 | 391 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 1992 | 501 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 503 | 0.080 |
Why?
|
| Macrophages | 1 | 2018 | 1496 | 0.080 |
Why?
|
| Gelatin | 2 | 2000 | 56 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 334 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2013 | 765 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2014 | 1033 | 0.080 |
Why?
|
| Communication | 1 | 2016 | 972 | 0.080 |
Why?
|
| Cell Shape | 1 | 2009 | 56 | 0.070 |
Why?
|
| Delivery, Obstetric | 1 | 1990 | 161 | 0.070 |
Why?
|
| Death, Sudden | 1 | 1989 | 24 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2001 | 161 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2001 | 61 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2001 | 82 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1766 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2013 | 657 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2012 | 396 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 435 | 0.070 |
Why?
|
| Cell Count | 1 | 2009 | 320 | 0.070 |
Why?
|
| Respirovirus Infections | 1 | 1988 | 14 | 0.070 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2008 | 2 | 0.070 |
Why?
|
| Endoglin | 1 | 2008 | 19 | 0.070 |
Why?
|
| Pressure | 2 | 2002 | 225 | 0.070 |
Why?
|
| Research | 1 | 2012 | 431 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2020 | 998 | 0.070 |
Why?
|
| Biopsy | 2 | 2024 | 1079 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 1322 | 0.070 |
Why?
|
| Cesarean Section | 3 | 2000 | 227 | 0.070 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2010 | 138 | 0.070 |
Why?
|
| Hyponatremia | 1 | 1988 | 43 | 0.070 |
Why?
|
| Pilot Projects | 4 | 2020 | 1886 | 0.070 |
Why?
|
| Meclofenamic Acid | 3 | 2001 | 9 | 0.070 |
Why?
|
| Dipeptides | 1 | 2008 | 56 | 0.070 |
Why?
|
| Islets of Langerhans | 1 | 2014 | 842 | 0.070 |
Why?
|
| Heart Failure | 1 | 2021 | 2324 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 1988 | 142 | 0.070 |
Why?
|
| Algorithms | 4 | 2024 | 1844 | 0.070 |
Why?
|
| Purinones | 2 | 1998 | 4 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2013 | 915 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2008 | 115 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 408 | 0.060 |
Why?
|
| Heart Rate, Fetal | 2 | 1999 | 31 | 0.060 |
Why?
|
| Staphylococcus | 2 | 2017 | 75 | 0.060 |
Why?
|
| Time | 2 | 2005 | 86 | 0.060 |
Why?
|
| Tolazoline | 1 | 1986 | 2 | 0.060 |
Why?
|
| Norepinephrine | 1 | 1987 | 196 | 0.060 |
Why?
|
| Cell Movement | 1 | 2011 | 959 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 118 | 0.060 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2006 | 9 | 0.060 |
Why?
|
| Diuretics | 2 | 2019 | 68 | 0.060 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1986 | 7 | 0.060 |
Why?
|
| Muscle, Smooth | 2 | 2000 | 153 | 0.060 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 2184 | 0.060 |
Why?
|
| Partial Pressure | 2 | 2002 | 30 | 0.060 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2005 | 393 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2006 | 52 | 0.060 |
Why?
|
| Nitric Oxide Donors | 1 | 2006 | 19 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1998 | 352 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2008 | 706 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2006 | 101 | 0.060 |
Why?
|
| Thiophenes | 1 | 2006 | 121 | 0.060 |
Why?
|
| Liver | 1 | 2014 | 1889 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 1998 | 605 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 1989 | 567 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2005 | 128 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 294 | 0.050 |
Why?
|
| Heart | 2 | 2000 | 626 | 0.050 |
Why?
|
| Myocardium | 2 | 2000 | 928 | 0.050 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2004 | 53 | 0.050 |
Why?
|
| Calcium | 3 | 1996 | 1182 | 0.050 |
Why?
|
| Blood Gas Analysis | 3 | 2000 | 81 | 0.050 |
Why?
|
| Cardiomegaly | 3 | 1997 | 174 | 0.050 |
Why?
|
| Postoperative Period | 2 | 1998 | 351 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 431 | 0.050 |
Why?
|
| Methacholine Chloride | 1 | 2024 | 50 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 2873 | 0.050 |
Why?
|
| Injections, Intra-Arterial | 2 | 2000 | 26 | 0.050 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 7 | 0.050 |
Why?
|
| Heart Atria | 1 | 2004 | 141 | 0.050 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 107 | 0.050 |
Why?
|
| Parturition | 1 | 2004 | 68 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 318 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 93 | 0.050 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 96 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2117 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1995 | 0.050 |
Why?
|
| Chromones | 1 | 2002 | 42 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.050 |
Why?
|
| Infant Death | 1 | 2022 | 9 | 0.050 |
Why?
|
| Hematocrit | 2 | 2000 | 108 | 0.050 |
Why?
|
| Arteriovenous Malformations | 1 | 2022 | 29 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 300 | 0.050 |
Why?
|
| Foreign Bodies | 1 | 1984 | 110 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 53 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2023 | 99 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2022 | 87 | 0.050 |
Why?
|
| Sex Factors | 2 | 2025 | 2104 | 0.040 |
Why?
|
| Gastrostomy | 2 | 2021 | 130 | 0.040 |
Why?
|
| Injections | 2 | 1994 | 197 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2022 | 191 | 0.040 |
Why?
|
| Nifedipine | 1 | 2002 | 27 | 0.040 |
Why?
|
| Morpholines | 1 | 2002 | 129 | 0.040 |
Why?
|
| Mosaicism | 1 | 2022 | 73 | 0.040 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 18 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2024 | 227 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 967 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2002 | 151 | 0.040 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 27 | 0.040 |
Why?
|
| Heterozygote | 2 | 2019 | 313 | 0.040 |
Why?
|
| Fetal Hypoxia | 1 | 2022 | 56 | 0.040 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 13 | 0.040 |
Why?
|
| Ciliary Motility Disorders | 1 | 2021 | 24 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2001 | 36 | 0.040 |
Why?
|
| Placentation | 1 | 2021 | 52 | 0.040 |
Why?
|
| Benzylamines | 1 | 2001 | 43 | 0.040 |
Why?
|
| Amidines | 1 | 2001 | 15 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2022 | 607 | 0.040 |
Why?
|
| Evidence-Based Medicine | 4 | 2007 | 732 | 0.040 |
Why?
|
| Pulmonary Ventilation | 1 | 2001 | 82 | 0.040 |
Why?
|
| Delayed Rectifier Potassium Channels | 1 | 2000 | 9 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2002 | 155 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 166 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 2000 | 14 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2001 | 311 | 0.040 |
Why?
|
| Ligands | 1 | 2003 | 662 | 0.040 |
Why?
|
| Plethysmography | 1 | 2001 | 104 | 0.040 |
Why?
|
| Cyclohexanes | 1 | 2000 | 23 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2000 | 87 | 0.040 |
Why?
|
| Quality of Life | 2 | 2010 | 3183 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 380 | 0.040 |
Why?
|
| Pediatricians | 1 | 2021 | 121 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 475 | 0.040 |
Why?
|
| Sesquiterpenes | 1 | 2000 | 52 | 0.040 |
Why?
|
| Insulin | 1 | 2011 | 2502 | 0.040 |
Why?
|
| Mutation | 2 | 2023 | 4081 | 0.040 |
Why?
|
| Thalidomide | 1 | 2000 | 43 | 0.040 |
Why?
|
| Exercise Test | 2 | 2019 | 626 | 0.040 |
Why?
|
| Heart Septum | 1 | 2000 | 27 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2001 | 401 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2001 | 245 | 0.040 |
Why?
|
| Vaping | 1 | 2021 | 66 | 0.040 |
Why?
|
| Barium | 1 | 2000 | 27 | 0.040 |
Why?
|
| Pharmacovigilance | 1 | 2020 | 23 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2000 | 96 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 393 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 371 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 221 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 144 | 0.040 |
Why?
|
| Physical Stimulation | 1 | 2000 | 68 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2000 | 30 | 0.040 |
Why?
|
| Perfusion | 2 | 1994 | 249 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2000 | 82 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2025 | 776 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 177 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 59 | 0.040 |
Why?
|
| Fever | 1 | 2001 | 313 | 0.040 |
Why?
|
| Ventricular Pressure | 2 | 2015 | 52 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
|
| Indazoles | 1 | 2000 | 82 | 0.040 |
Why?
|
| Middle Aged | 5 | 2026 | 35971 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 58 | 0.040 |
Why?
|
| Charybdotoxin | 1 | 1999 | 4 | 0.040 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 16 | 0.040 |
Why?
|
| Gingiva | 1 | 2019 | 25 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 81 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2002 | 451 | 0.040 |
Why?
|
| Societies | 1 | 2019 | 40 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 1999 | 73 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 30 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2022 | 519 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2002 | 208 | 0.040 |
Why?
|
| Atrial Function, Right | 1 | 1998 | 14 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 120 | 0.040 |
Why?
|
| Progestins | 1 | 2019 | 65 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 44 | 0.040 |
Why?
|
| Caffeine | 1 | 2019 | 74 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 2019 | 60 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 1044 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 184 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 99 | 0.030 |
Why?
|
| North America | 1 | 2019 | 312 | 0.030 |
Why?
|
| Asphyxia Neonatorum | 1 | 1998 | 21 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 619 | 0.030 |
Why?
|
| Nutritional Status | 2 | 1992 | 351 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2001 | 410 | 0.030 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 1999 | 335 | 0.030 |
Why?
|
| Nose | 1 | 1998 | 68 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2022 | 1103 | 0.030 |
Why?
|
| Thiazines | 1 | 1998 | 13 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2019 | 227 | 0.030 |
Why?
|
| Masks | 1 | 1998 | 70 | 0.030 |
Why?
|
| Air Pollution | 1 | 2021 | 318 | 0.030 |
Why?
|
| Catheterization | 1 | 1998 | 183 | 0.030 |
Why?
|
| Progesterone | 1 | 2019 | 209 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2018 | 82 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1998 | 117 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 171 | 0.030 |
Why?
|
| Phentolamine | 2 | 1987 | 19 | 0.030 |
Why?
|
| Hospitals | 1 | 2022 | 729 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 402 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 191 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 386 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1997 | 88 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2020 | 308 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2017 | 61 | 0.030 |
Why?
|
| Shear Strength | 1 | 2017 | 73 | 0.030 |
Why?
|
| Leg | 1 | 2019 | 240 | 0.030 |
Why?
|
| Methylene Blue | 1 | 1996 | 24 | 0.030 |
Why?
|
| Travel | 1 | 2018 | 136 | 0.030 |
Why?
|
| Education | 1 | 2017 | 105 | 0.030 |
Why?
|
| Indomethacin | 1 | 1996 | 76 | 0.030 |
Why?
|
| Biological Products | 1 | 2000 | 256 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2136 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 547 | 0.030 |
Why?
|
| Expectorants | 1 | 2016 | 23 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 317 | 0.030 |
Why?
|
| Growth | 2 | 1997 | 49 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 161 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2019 | 322 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1246 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 195 | 0.030 |
Why?
|
| Adenosine | 1 | 1998 | 255 | 0.030 |
Why?
|
| Iron | 1 | 2019 | 358 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1997 | 104 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 355 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 2909 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 75 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 727 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 94 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2004 | 630 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.030 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 31 | 0.030 |
Why?
|
| Fellowships and Scholarships | 2 | 2010 | 355 | 0.030 |
Why?
|
| Parents | 1 | 2024 | 1395 | 0.030 |
Why?
|
| Theophylline | 1 | 1995 | 41 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 651 | 0.030 |
Why?
|
| Arterioles | 1 | 1995 | 52 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 381 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 83 | 0.030 |
Why?
|
| Phenylephrine | 1 | 1995 | 74 | 0.030 |
Why?
|
| Catalase | 1 | 2015 | 133 | 0.030 |
Why?
|
| Cysteine Dioxygenase | 1 | 2014 | 3 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1999 | 2033 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 854 | 0.030 |
Why?
|
| Carboxy-Lyases | 1 | 2014 | 10 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1994 | 6 | 0.030 |
Why?
|
| Sepharose | 1 | 1994 | 32 | 0.030 |
Why?
|
| Frozen Sections | 1 | 1994 | 24 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 985 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2009 | 221 | 0.030 |
Why?
|
| Netherlands | 1 | 2013 | 82 | 0.030 |
Why?
|
| Guanosine Monophosphate | 1 | 2013 | 8 | 0.030 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1993 | 12 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1993 | 79 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2019 | 813 | 0.020 |
Why?
|
| Methionine | 1 | 2014 | 162 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 165 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 852 | 0.020 |
Why?
|
| Comorbidity | 1 | 2018 | 1652 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2013 | 49 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 944 | 0.020 |
Why?
|
| Cromakalim | 1 | 1992 | 1 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 319 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 915 | 0.020 |
Why?
|
| Glyburide | 1 | 1992 | 31 | 0.020 |
Why?
|
| Benzopyrans | 1 | 1992 | 30 | 0.020 |
Why?
|
| Cytosol | 1 | 1993 | 214 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 5870 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 631 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 1494 | 0.020 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1992 | 24 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 586 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 601 | 0.020 |
Why?
|
| Verapamil | 2 | 1994 | 37 | 0.020 |
Why?
|
| Trypsinogen | 1 | 1991 | 11 | 0.020 |
Why?
|
| Venae Cavae | 1 | 1991 | 7 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 380 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1991 | 70 | 0.020 |
Why?
|
| Pharynx | 1 | 1991 | 59 | 0.020 |
Why?
|
| Platelet Activating Factor | 1 | 1991 | 45 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 1990 | 29 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 1991 | 171 | 0.020 |
Why?
|
| Vitamin E Deficiency | 1 | 1991 | 43 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1991 | 83 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 67 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1991 | 22 | 0.020 |
Why?
|
| Vitamin A Deficiency | 1 | 1991 | 26 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 160 | 0.020 |
Why?
|
| Pancreatin | 2 | 1991 | 6 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 1078 | 0.020 |
Why?
|
| Muscle Development | 1 | 1991 | 113 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 960 | 0.020 |
Why?
|
| Aged | 2 | 2021 | 25955 | 0.020 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 43 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 2183 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2009 | 17 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2009 | 50 | 0.020 |
Why?
|
| Accreditation | 1 | 2010 | 101 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 132 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1991 | 230 | 0.020 |
Why?
|
| Critical Care | 1 | 1995 | 695 | 0.020 |
Why?
|
| Pulmonary Heart Disease | 1 | 1988 | 7 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 141 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 8284 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1991 | 391 | 0.020 |
Why?
|
| Sheep Diseases | 1 | 1988 | 9 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 143 | 0.020 |
Why?
|
| Brain | 2 | 2017 | 2934 | 0.020 |
Why?
|
| Chest Wall Oscillation | 1 | 2007 | 5 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 3070 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1987 | 34 | 0.020 |
Why?
|
| Kinetics | 1 | 1991 | 1602 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 288 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1991 | 454 | 0.020 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
|
| Cimetidine | 1 | 1986 | 12 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 46 | 0.020 |
Why?
|
| Epinephrine | 1 | 1987 | 154 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 1986 | 36 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 638 | 0.020 |
Why?
|
| Hypoproteinemia | 1 | 1986 | 5 | 0.020 |
Why?
|
| Pancreatic Extracts | 1 | 1985 | 2 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1985 | 5 | 0.010 |
Why?
|
| Pancrelipase | 1 | 1985 | 6 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2754 | 0.010 |
Why?
|
| Edema | 1 | 1986 | 124 | 0.010 |
Why?
|
| Lipase | 1 | 1985 | 75 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 848 | 0.010 |
Why?
|
| Failure to Thrive | 1 | 1984 | 28 | 0.010 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 562 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 1984 | 7 | 0.010 |
Why?
|
| Anemia | 1 | 1986 | 189 | 0.010 |
Why?
|
| Propranolol | 1 | 1984 | 44 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1986 | 247 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 356 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 269 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 523 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 175 | 0.010 |
Why?
|
| Heart Rate | 1 | 1986 | 853 | 0.010 |
Why?
|
| Child Health Services | 1 | 1984 | 185 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1981 | 33 | 0.010 |
Why?
|
| Ebstein Anomaly | 1 | 1981 | 7 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 39 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 48 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 120 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2004 | 664 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 70 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2000 | 80 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 151 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2000 | 14 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2000 | 101 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 110 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 234 | 0.010 |
Why?
|
| Vitamin E | 2 | 1991 | 123 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 229 | 0.010 |
Why?
|
| CREST Syndrome | 1 | 1999 | 6 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1999 | 46 | 0.010 |
Why?
|
| Rats, Mutant Strains | 1 | 1999 | 19 | 0.010 |
Why?
|
| Monocrotaline | 1 | 1999 | 31 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 249 | 0.010 |
Why?
|
| Homozygote | 1 | 1999 | 200 | 0.010 |
Why?
|
| Occipital Bone | 1 | 1997 | 18 | 0.010 |
Why?
|
| Frontal Bone | 1 | 1997 | 19 | 0.010 |
Why?
|
| Cephalometry | 1 | 1997 | 30 | 0.010 |
Why?
|
| Child Development | 2 | 1997 | 482 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 287 | 0.010 |
Why?
|
| Mass Screening | 1 | 1985 | 1348 | 0.010 |
Why?
|
| Body Height | 1 | 1997 | 199 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 217 | 0.010 |
Why?
|
| Fixatives | 1 | 1994 | 13 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2000 | 1106 | 0.010 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1994 | 11 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 328 | 0.010 |
Why?
|
| Ryanodine | 1 | 1994 | 15 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1994 | 64 | 0.010 |
Why?
|
| Manganese | 1 | 1994 | 54 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1994 | 218 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 153 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1993 | 95 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1992 | 53 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 1993 | 207 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1991 | 61 | 0.010 |
Why?
|
| Anthropometry | 1 | 1992 | 197 | 0.010 |
Why?
|
| Sweat | 1 | 1991 | 51 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1991 | 122 | 0.010 |
Why?
|
| Phospholipid Ethers | 1 | 1991 | 4 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1992 | 135 | 0.010 |
Why?
|
| Polymers | 1 | 1994 | 492 | 0.000 |
Why?
|
| Hydroxycholecalciferols | 1 | 1989 | 3 | 0.000 |
Why?
|
| Dietary Fats | 1 | 1992 | 308 | 0.000 |
Why?
|
| Infant Nutrition Disorders | 1 | 1989 | 10 | 0.000 |
Why?
|
| Clinical Protocols | 1 | 1991 | 282 | 0.000 |
Why?
|
| Vitamin K | 1 | 1989 | 45 | 0.000 |
Why?
|
| Solubility | 1 | 1989 | 236 | 0.000 |
Why?
|
| Energy Intake | 1 | 1992 | 501 | 0.000 |
Why?
|
| Breast Feeding | 1 | 1992 | 444 | 0.000 |
Why?
|
| Genotype | 1 | 1993 | 1847 | 0.000 |
Why?
|
| Lipids | 1 | 1989 | 706 | 0.000 |
Why?
|
| HIV Infections | 1 | 1999 | 3148 | 0.000 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1984 | 80 | 0.000 |
Why?
|
| Digoxin | 1 | 1981 | 27 | 0.000 |
Why?
|
| Furosemide | 1 | 1981 | 37 | 0.000 |
Why?
|